Organisation paid for research Program year 2025 Source: CMS Open Payments

FDI Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,858,285

140 payments

Through program year 2025, FDI Clinical Research is reported as receiving $2,858,285 in research payments, across 140 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $234,934 20
2024 Research $799,055 23
2023 Research $882,362 25
2022 Research $833,002 49
2021 Research $108,932 23

Breakdown

Who paid Research payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $1,633,605 11 payments
  2. Merck Sharp & Dohme Corporation $565,426 21 payments
  3. Madrigal Pharmaceuticals $265,511 21 payments
  4. CSL Behring $129,869 22 payments
  5. Intercept Pharmaceuticals, Inc. $98,288 31 payments
  6. Daiichi Sankyo Inc. $81,940 13 payments
  7. Intercept Pharma Europe Ltd. $42,615 7 payments
  8. Genentech, Inc. $18,040 2 payments
  9. Bausch Health US, LLC $9,600 1 payment
  10. Sumitomo Pharma America, Inc. $6,500 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. PhII 1L HCC Rela+Nivo+Bev vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma $1,408,807 4 payments
  2. A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in Participants with Incurable,Non-metastatic Hepatocellular Carcinoma LEAP-012 $436,646 8 payments
  3. A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $265,511 21 payments
  4. A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease $129,869 22 payments
  5. Phase III MSS 3L CRC Rela+Nivo vs. regorafenib/TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Color $91,350 2 payments
  6. Phase III MSS 3L CRC Rela Nivo vs. regorafenib TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Color $90,308 1 payment
  7. Ds1062-A-U301 $81,940 13 payments
  8. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $74,370 20 payments
  9. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $66,533 18 payments
  10. A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P $63,061 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record